Drug intelligence / Profile preview

Autoimmune Program 2

Development stage: Preclinical
Lead developer: Amgen

Overview

Autoimmune Program 2 is a preclinical research and development collaboration between TScan Therapeutics and Amgen, focused on the treatment of Crohn's disease. The program leverages TScan's proprietary TargetScan platform to identify novel antigens recognized by T cells, specifically focusing on MHC class II targets of CD4+ T cells in patients with Crohn's disease. Once specific biological targets are identified, Amgen will evaluate various therapeutic modalities to develop drug candidates and will hold global development and commercialization rights. The collaboration, announced in May 2023, includes an upfront payment and potential milestone payments exceeding $500 million.

Other names: TScan-Amgen Crohn's disease collaboration

Beyond the preview

Go deeper on Autoimmune Program 2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Autoimmune Program 2.

Explore the full profile